Dan Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dan Chen has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Bozhen Zhang
PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, China
22 shared publications - Changsong Qi
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Early Drug Development Centre, Peking University Cancer Hospital & Institute, Beijing 100142, China
22 shared publications - Fengtao You
PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, China
22 shared publications - Gangli An
Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China
22 shared publications - Hai Wu
Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China
22 shared publications - Huimin Meng
PersonGen BioTherapeutics (Suzhou) Co., Ltd, Suzhou, China
22 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
Functional comparison of various CAR structures carrying different cytokines in vitro
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
Functional comparison of various CAR structures carrying different cytokines in vitro
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
Safety study of IL-2 release from AQ-CAR-IL2-Vδ1T cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
Safety study of IL-2 release from AQ-CAR-IL2-Vδ1T cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
The efficacy and infiltration of AQ-CAR-IL2-Vδ1T cells in the HCT-15 tumor model
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
The efficacy and infiltration of AQ-CAR-IL2-Vδ1T cells in the HCT-15 tumor model
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
Supporting data of Vδ1T cells preparation in vitro
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
Supporting data of Vδ1T cells preparation in vitro
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
The B7-H3 expression of tumor cells involved in this study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
The B7-H3 expression of tumor cells involved in this study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
In vitro cytotoxicity of AQ-CAR-IL2-Vδ1T against B7-H3 positive MDA-MB-231 cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
In vitro cytotoxicity of AQ-CAR-IL2-Vδ1T against B7-H3 positive MDA-MB-231 cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
The supporting data of single-cell RNA sequencing between AQ-CAR-IL2-Vδ1T cells and AG-CAR-Vδ1T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
The supporting data of single-cell RNA sequencing between AQ-CAR-IL2-Vδ1T cells and AG-CAR-Vδ1T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
AQ-CAR-IL2-Vδ1T cells exhibited obvious antitumor efficacy in the acute myeloid leukemia AML-3 model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
AQ-CAR-IL2-Vδ1T cells exhibited obvious antitumor efficacy in the acute myeloid leukemia AML-3 model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
Supporting data for efficacy comparison of three CART cells in vivo
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
Supporting data for efficacy comparison of three CART cells in vivo